Coronavirus: Difference between revisions
Ktanner777 (talk | contribs) |
Ktanner777 (talk | contribs) |
||
| Line 21: | Line 21: | ||
==Evaluation== | ==Evaluation== | ||
*PCR Testing | *PCR Testing | ||
**Should be obtained on nasopharyngeal swab preferably one with synthetic fibers and plastic tip and under isolation | **Should be obtained on nasopharyngeal swab preferably one with synthetic fibers and plastic tip and under isolation | ||
**Criteria for who to test is constantly evolving at this time. The CDC currently recommends clinicians to refer to local and/or institutional guidelines and test availability when deciding who should be tested. | **Criteria for who to test is constantly evolving at this time. The CDC currently recommends clinicians to refer to local and/or institutional guidelines and test availability when deciding who should be tested. | ||
*Laboratory Abnormalities | |||
**Lymphocytosis | **Lymphocytosis | ||
***Present in 70-80% of patients<ref>Wang D, Hu B, Hu C, et al. Clinical Characteristics of 138 Hospitalized Patients With 2019 Novel Coronavirus-Infected Pneumonia in Wuhan, China [published online ahead of print, 2020 Feb 7]. JAMA. 2020;10.1001/jama.2020.1585. doi:10.1001/jama.2020.1585</ref> | ***Present in 70-80% of patients<ref name="clinical characteristics">Wang D, Hu B, Hu C, et al. Clinical Characteristics of 138 Hospitalized Patients With 2019 Novel Coronavirus-Infected Pneumonia in Wuhan, China [published online ahead of print, 2020 Feb 7]. JAMA. 2020;10.1001/jama.2020.1585. doi:10.1001/jama.2020.1585</ref> | ||
***Severity of lymphocytosis and leukopenia shown to be associated with severe of illness<ref> | ***Severity of lymphocytosis and leukopenia shown to be associated with severe of illness<ref name="clinical characteristics"></ref><ref name="disease 2019">Wei-jie Guan, Ph.D., Zheng-yi Ni, M.D., Yu Hu, M.D., et al. Clinical Characteristics of Coronavirus Disease 2019 in China. China Medical Treatment Expert Group for Covid-19. The New England Journal Of Medicine website. https://www.nejm.org/doi/full/10.1056/NEJMoa2002032 Published February 28, 2020. Accessed March 31, 2020</ref> | ||
**Thrombocytopenia, elevated lactate dehydrogenase, elevated C-reactive protein, and prolonged prothrombin time have been reported<ref> | **Thrombocytopenia, elevated lactate dehydrogenase, elevated C-reactive protein, and prolonged prothrombin time have been reported<ref name="clinical characteristics"></ref><ref name="disease 2019"></ref> | ||
==Management== | ==Management== | ||
Revision as of 17:53, 31 March 2020
Background
- Enveloped, positive-stranded RNA viruses with nucleocapsid
- Very common cause of upper respiratory infection, especially during fall and winter, and some diarrhea in pediatric patients
Clinical Features
- Incubation period: 2-4 days
- Upper respiratory symptoms
- Rhinorrhea, cough, sore throat, earache, fever, malaise
- Respiratory symptoms may be more severe in elderly/immunocompromised (e.g. pneumonia, secondary bacterial pneumonia)
- GI symptoms - vomiting, diarrhea, Necrotizing enterocolitis (in neonates)
Differential Diagnosis
- Rhinovirus: most common cold virus. Causes around 40% colds.
- as opposed to Coronavirus, this causes cold in other seasons besides winter.
- Rhinovirus is NOT encapsulated as opposed to Coronavirus.
- respiratory syncytial virus (RSV)
- influenza
- parainfluenza
Evaluation
- PCR Testing
- Should be obtained on nasopharyngeal swab preferably one with synthetic fibers and plastic tip and under isolation
- Criteria for who to test is constantly evolving at this time. The CDC currently recommends clinicians to refer to local and/or institutional guidelines and test availability when deciding who should be tested.
- Laboratory Abnormalities
Management
- There is no specific treatment for Coronavirus, since most infections spontaneously resolve.
- Supportive care, no specific treatment
- Rest, hydration, analgesia, antipyretics
- Hand hygiene to prevent spread
Disposition
Prevention
- No vaccines have been made thus far to prevent Coronavirus.
- Measures to reduce risk of transmission: fully wash hands, do not touch face without washing hands, avoid close contact with sick contacts.
See Also
External Links
References
- ↑ 1.0 1.1 1.2 Wang D, Hu B, Hu C, et al. Clinical Characteristics of 138 Hospitalized Patients With 2019 Novel Coronavirus-Infected Pneumonia in Wuhan, China [published online ahead of print, 2020 Feb 7]. JAMA. 2020;10.1001/jama.2020.1585. doi:10.1001/jama.2020.1585
- ↑ 2.0 2.1 Wei-jie Guan, Ph.D., Zheng-yi Ni, M.D., Yu Hu, M.D., et al. Clinical Characteristics of Coronavirus Disease 2019 in China. China Medical Treatment Expert Group for Covid-19. The New England Journal Of Medicine website. https://www.nejm.org/doi/full/10.1056/NEJMoa2002032 Published February 28, 2020. Accessed March 31, 2020